Real-World Effectiveness of Dulaglutide in Patients with Type 2 Diabetes Mellitus: A Literature Review View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2020-06-10

AUTHORS

Susan Robinson, Kristina S. Boye, Reema Mody, Alena Antonie Strizek, Manige Konig, Raleigh E. Malik, Tessa Kennedy-Martin

ABSTRACT

IntroductionRandomized controlled trials (RCTs) have demonstrated the efficacy of dulaglutide in adults with type 2 diabetes mellitus (T2DM), but results may not be generalizable in routine practice. This pragmatic literature review aimed to summarize real-world evidence (RWE) for dulaglutide.MethodsThe MEDLINE, EMBASE, NHS Economic Evaluation Database, and Health Technology Assessment databases were searched from January 2014 to July 2019 for studies providing RWE for dulaglutide in adults with T2DM regarding at least one outcome of interest (change in glycated hemoglobin [HbA1c]; weight; adherence; persistence; discontinuation; costs; healthcare resource utilization; health-related quality of life; patient satisfaction; and preference). Relevant congress abstracts were identified from EMBASE.ResultsA total of 29 studies (11 articles; 18 abstracts) were included. RWE for dulaglutide was not identified for all outcomes of interest. Dulaglutide reduced HbA1c from baseline to 3–24 months by 0.5–2.2% across studies (n = 20), and 23.4–55.7% of patients achieved HbA1c < 7.0%. Weight was reduced by 2.1–6.4 kg across studies of 3–12 months (n = 15). Based on outcomes from ten studies, 27.2–61.0% of dulaglutide patients were adherent. Mean persistence was 146–152 days and > 250 days in 6- and 12-month studies, respectively. Most studies reported discontinuation rates of 26.2–37.0%. Adherence and persistence were consistently reported to be greater in dulaglutide-treated patients in RW settings compared with other glucagon-like peptide-1 receptor agonists. Dulaglutide was associated with lower costs per 1% reduction in HbA1c compared with exenatide, liraglutide, or basal insulin (n = 3 studies).ConclusionEvidence from RWE studies suggests that dulaglutide may be associated with clinically relevant reductions in HbA1c, with a favorable adherence, persistence, and discontinuation profile in patients with T2DM in routine clinical practice. These findings provide additional insights regarding the potential value of dulaglutide in real-world settings that may assist healthcare decision makers in the delivery of patient-centered care. More... »

PAGES

1437-1466

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s13300-020-00839-5

DOI

http://dx.doi.org/10.1007/s13300-020-00839-5

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1128395219

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/32524494


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1103", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Clinical Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1117", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Public Health and Health Services", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Kennedy Martin Health Outcomes (KMHO) Limited, Suite 404, The Dock Hub, Wilbury Villas, BN3 6AH, Hove, UK", 
          "id": "http://www.grid.ac/institutes/grid.459720.d", 
          "name": [
            "Kennedy Martin Health Outcomes (KMHO) Limited, Suite 404, The Dock Hub, Wilbury Villas, BN3 6AH, Hove, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Robinson", 
        "givenName": "Susan", 
        "id": "sg:person.0632033303.17", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0632033303.17"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Global Patient Outcomes and Real-World Evidence, Eli Lilly, Indianapolis, IN, USA", 
          "id": "http://www.grid.ac/institutes/grid.417540.3", 
          "name": [
            "Global Patient Outcomes and Real-World Evidence, Eli Lilly, Indianapolis, IN, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Boye", 
        "givenName": "Kristina S.", 
        "id": "sg:person.01033602257.87", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01033602257.87"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Global Patient Outcomes and Real-World Evidence, Eli Lilly, Indianapolis, IN, USA", 
          "id": "http://www.grid.ac/institutes/grid.417540.3", 
          "name": [
            "Global Patient Outcomes and Real-World Evidence, Eli Lilly, Indianapolis, IN, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Mody", 
        "givenName": "Reema", 
        "id": "sg:person.01167170416.01", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01167170416.01"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Formerly of Global Patient Outcomes and Real-World Evidence, Eli Lilly, Sydney, Australia", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "Formerly of Global Patient Outcomes and Real-World Evidence, Eli Lilly, Sydney, Australia"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Strizek", 
        "givenName": "Alena Antonie", 
        "id": "sg:person.013775775106.11", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.013775775106.11"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Medical Affairs, Eli Lilly, Indianapolis, IN, USA", 
          "id": "http://www.grid.ac/institutes/grid.417540.3", 
          "name": [
            "Medical Affairs, Eli Lilly, Indianapolis, IN, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Konig", 
        "givenName": "Manige", 
        "id": "sg:person.0733105733.74", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0733105733.74"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Medical Affairs, Eli Lilly, Indianapolis, IN, USA", 
          "id": "http://www.grid.ac/institutes/grid.417540.3", 
          "name": [
            "Medical Affairs, Eli Lilly, Indianapolis, IN, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Malik", 
        "givenName": "Raleigh E.", 
        "id": "sg:person.01102001105.13", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01102001105.13"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Kennedy Martin Health Outcomes (KMHO) Limited, Suite 404, The Dock Hub, Wilbury Villas, BN3 6AH, Hove, UK", 
          "id": "http://www.grid.ac/institutes/grid.459720.d", 
          "name": [
            "Kennedy Martin Health Outcomes (KMHO) Limited, Suite 404, The Dock Hub, Wilbury Villas, BN3 6AH, Hove, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Kennedy-Martin", 
        "givenName": "Tessa", 
        "id": "sg:person.0654034520.21", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0654034520.21"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1007/s12325-018-0805-y", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1107826098", 
          "https://doi.org/10.1007/s12325-018-0805-y"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s13300-021-01076-0", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1138660220", 
          "https://doi.org/10.1007/s13300-021-01076-0"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s13300-018-0396-2", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1101407058", 
          "https://doi.org/10.1007/s13300-018-0396-2"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1186/s40842-018-0061-8", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1103875516", 
          "https://doi.org/10.1186/s40842-018-0061-8"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s13300-019-0658-7", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1117490480", 
          "https://doi.org/10.1007/s13300-019-0658-7"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s13300-019-0615-5", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1113754031", 
          "https://doi.org/10.1007/s13300-019-0615-5"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00125-018-4729-5", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1107409514", 
          "https://doi.org/10.1007/s00125-018-4729-5"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2020-06-10", 
    "datePublishedReg": "2020-06-10", 
    "description": "IntroductionRandomized controlled trials (RCTs) have demonstrated the efficacy of dulaglutide in adults with type 2 diabetes mellitus (T2DM), but results may not be generalizable in routine practice. This pragmatic literature review aimed to summarize real-world evidence (RWE) for dulaglutide.MethodsThe MEDLINE, EMBASE, NHS Economic Evaluation Database, and Health Technology Assessment databases were searched from January 2014 to July 2019 for studies providing RWE for dulaglutide in adults with T2DM regarding at least one outcome of interest (change in glycated hemoglobin [HbA1c]; weight; adherence; persistence; discontinuation; costs; healthcare resource utilization; health-related quality of life; patient satisfaction; and preference). Relevant congress abstracts were identified from EMBASE.ResultsA total of 29 studies (11 articles; 18 abstracts) were included. RWE for dulaglutide was not identified for all outcomes of interest. Dulaglutide reduced HbA1c from baseline to 3\u201324\u00a0months by 0.5\u20132.2% across studies (n\u2009=\u200920), and 23.4\u201355.7% of patients achieved HbA1c\u2009<\u20097.0%. Weight was reduced by 2.1\u20136.4\u00a0kg across studies of 3\u201312\u00a0months (n\u2009=\u200915). Based on outcomes from ten studies, 27.2\u201361.0% of dulaglutide patients were adherent. Mean persistence was 146\u2013152\u00a0days and\u2009>\u2009250\u00a0days in 6- and 12-month studies, respectively. Most studies reported discontinuation rates of 26.2\u201337.0%. Adherence and persistence were consistently reported to be greater in dulaglutide-treated patients in RW settings compared with other glucagon-like peptide-1 receptor agonists. Dulaglutide was associated with lower costs per 1% reduction in HbA1c compared with exenatide, liraglutide, or basal insulin (n\u2009=\u20093 studies).ConclusionEvidence\u00a0from RWE studies suggests that dulaglutide may be associated with clinically relevant reductions in HbA1c, with a favorable adherence, persistence, and discontinuation profile in patients with T2DM in routine clinical practice. These findings provide additional insights regarding the potential value of dulaglutide in real-world settings that may assist healthcare decision makers in the delivery of patient-centered care.", 
    "genre": "article", 
    "id": "sg:pub.10.1007/s13300-020-00839-5", 
    "isAccessibleForFree": true, 
    "isPartOf": [
      {
        "id": "sg:journal.1044057", 
        "issn": [
          "1869-6953", 
          "1869-6961"
        ], 
        "name": "Diabetes Therapy", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "7", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "11"
      }
    ], 
    "keywords": [
      "real-world evidence", 
      "outcomes of interest", 
      "glucagon-like peptide-1 receptor agonists", 
      "peptide-1 receptor agonists", 
      "type 2 diabetes mellitus", 
      "Health Technology Assessment Database", 
      "NHS Economic Evaluation Database", 
      "efficacy of dulaglutide", 
      "relevant congress abstracts", 
      "dulaglutide-treated patients", 
      "routine clinical practice", 
      "Economic Evaluation Database", 
      "patient-centered care", 
      "pragmatic literature review", 
      "discontinuation profiles", 
      "discontinuation rates", 
      "diabetes mellitus", 
      "basal insulin", 
      "congress abstracts", 
      "ResultsA total", 
      "World Effectiveness", 
      "receptor agonist", 
      "dulaglutide", 
      "MethodsThe MEDLINE", 
      "healthcare decision makers", 
      "patients", 
      "clinical practice", 
      "type 2", 
      "routine practice", 
      "real-world setting", 
      "RWE studies", 
      "favorable adherence", 
      "relevant reduction", 
      "literature review", 
      "Evaluation Database", 
      "mean persistence", 
      "HbA1c", 
      "mellitus", 
      "T2DM", 
      "EMBASE", 
      "RW settings", 
      "outcomes", 
      "months", 
      "adherence", 
      "Assessment Database", 
      "adults", 
      "most studies", 
      "days", 
      "liraglutide", 
      "exenatide", 
      "review", 
      "MEDLINE", 
      "agonists", 
      "ConclusionEvidence", 
      "study", 
      "insulin", 
      "setting", 
      "trials", 
      "baseline", 
      "care", 
      "efficacy", 
      "persistence", 
      "potential value", 
      "total", 
      "database", 
      "reduction", 
      "delivery", 
      "adherent", 
      "findings", 
      "practice", 
      "evidence", 
      "additional insight", 
      "weight", 
      "rate", 
      "profile", 
      "effectiveness", 
      "results", 
      "interest", 
      "values", 
      "insights", 
      "Abstract", 
      "cost", 
      "low cost", 
      "makers", 
      "decision makers"
    ], 
    "name": "Real-World Effectiveness of Dulaglutide in Patients with Type 2 Diabetes Mellitus: A Literature Review", 
    "pagination": "1437-1466", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1128395219"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s13300-020-00839-5"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "32524494"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s13300-020-00839-5", 
      "https://app.dimensions.ai/details/publication/pub.1128395219"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2022-09-02T16:05", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20220902/entities/gbq_results/article/article_842.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1007/s13300-020-00839-5"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s13300-020-00839-5'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s13300-020-00839-5'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s13300-020-00839-5'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s13300-020-00839-5'


 

This table displays all metadata directly associated to this object as RDF triples.

228 TRIPLES      21 PREDICATES      118 URIs      102 LITERALS      7 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s13300-020-00839-5 schema:about anzsrc-for:11
2 anzsrc-for:1103
3 anzsrc-for:1117
4 schema:author N489dcf1b889c4ba0985f468b07fef959
5 schema:citation sg:pub.10.1007/s00125-018-4729-5
6 sg:pub.10.1007/s12325-018-0805-y
7 sg:pub.10.1007/s13300-018-0396-2
8 sg:pub.10.1007/s13300-019-0615-5
9 sg:pub.10.1007/s13300-019-0658-7
10 sg:pub.10.1007/s13300-021-01076-0
11 sg:pub.10.1186/s40842-018-0061-8
12 schema:datePublished 2020-06-10
13 schema:datePublishedReg 2020-06-10
14 schema:description IntroductionRandomized controlled trials (RCTs) have demonstrated the efficacy of dulaglutide in adults with type 2 diabetes mellitus (T2DM), but results may not be generalizable in routine practice. This pragmatic literature review aimed to summarize real-world evidence (RWE) for dulaglutide.MethodsThe MEDLINE, EMBASE, NHS Economic Evaluation Database, and Health Technology Assessment databases were searched from January 2014 to July 2019 for studies providing RWE for dulaglutide in adults with T2DM regarding at least one outcome of interest (change in glycated hemoglobin [HbA1c]; weight; adherence; persistence; discontinuation; costs; healthcare resource utilization; health-related quality of life; patient satisfaction; and preference). Relevant congress abstracts were identified from EMBASE.ResultsA total of 29 studies (11 articles; 18 abstracts) were included. RWE for dulaglutide was not identified for all outcomes of interest. Dulaglutide reduced HbA1c from baseline to 3–24 months by 0.5–2.2% across studies (n = 20), and 23.4–55.7% of patients achieved HbA1c < 7.0%. Weight was reduced by 2.1–6.4 kg across studies of 3–12 months (n = 15). Based on outcomes from ten studies, 27.2–61.0% of dulaglutide patients were adherent. Mean persistence was 146–152 days and > 250 days in 6- and 12-month studies, respectively. Most studies reported discontinuation rates of 26.2–37.0%. Adherence and persistence were consistently reported to be greater in dulaglutide-treated patients in RW settings compared with other glucagon-like peptide-1 receptor agonists. Dulaglutide was associated with lower costs per 1% reduction in HbA1c compared with exenatide, liraglutide, or basal insulin (n = 3 studies).ConclusionEvidence from RWE studies suggests that dulaglutide may be associated with clinically relevant reductions in HbA1c, with a favorable adherence, persistence, and discontinuation profile in patients with T2DM in routine clinical practice. These findings provide additional insights regarding the potential value of dulaglutide in real-world settings that may assist healthcare decision makers in the delivery of patient-centered care.
15 schema:genre article
16 schema:isAccessibleForFree true
17 schema:isPartOf N3ba91b98bfee4cb780701388eb09d9f4
18 Ndfed84f958454cf1a39f274580b2d877
19 sg:journal.1044057
20 schema:keywords Abstract
21 Assessment Database
22 ConclusionEvidence
23 EMBASE
24 Economic Evaluation Database
25 Evaluation Database
26 HbA1c
27 Health Technology Assessment Database
28 MEDLINE
29 MethodsThe MEDLINE
30 NHS Economic Evaluation Database
31 RW settings
32 RWE studies
33 ResultsA total
34 T2DM
35 World Effectiveness
36 additional insight
37 adherence
38 adherent
39 adults
40 agonists
41 basal insulin
42 baseline
43 care
44 clinical practice
45 congress abstracts
46 cost
47 database
48 days
49 decision makers
50 delivery
51 diabetes mellitus
52 discontinuation profiles
53 discontinuation rates
54 dulaglutide
55 dulaglutide-treated patients
56 effectiveness
57 efficacy
58 efficacy of dulaglutide
59 evidence
60 exenatide
61 favorable adherence
62 findings
63 glucagon-like peptide-1 receptor agonists
64 healthcare decision makers
65 insights
66 insulin
67 interest
68 liraglutide
69 literature review
70 low cost
71 makers
72 mean persistence
73 mellitus
74 months
75 most studies
76 outcomes
77 outcomes of interest
78 patient-centered care
79 patients
80 peptide-1 receptor agonists
81 persistence
82 potential value
83 practice
84 pragmatic literature review
85 profile
86 rate
87 real-world evidence
88 real-world setting
89 receptor agonist
90 reduction
91 relevant congress abstracts
92 relevant reduction
93 results
94 review
95 routine clinical practice
96 routine practice
97 setting
98 study
99 total
100 trials
101 type 2
102 type 2 diabetes mellitus
103 values
104 weight
105 schema:name Real-World Effectiveness of Dulaglutide in Patients with Type 2 Diabetes Mellitus: A Literature Review
106 schema:pagination 1437-1466
107 schema:productId N3769c34120924ae9a9f26f04f0b54239
108 N555795172a004829a9fcc0a92b4d16fc
109 Ne7acc6ad7eac48179b422f0b108c20dc
110 schema:sameAs https://app.dimensions.ai/details/publication/pub.1128395219
111 https://doi.org/10.1007/s13300-020-00839-5
112 schema:sdDatePublished 2022-09-02T16:05
113 schema:sdLicense https://scigraph.springernature.com/explorer/license/
114 schema:sdPublisher N0221c66911f94f24b98f1dd2576bdad5
115 schema:url https://doi.org/10.1007/s13300-020-00839-5
116 sgo:license sg:explorer/license/
117 sgo:sdDataset articles
118 rdf:type schema:ScholarlyArticle
119 N0221c66911f94f24b98f1dd2576bdad5 schema:name Springer Nature - SN SciGraph project
120 rdf:type schema:Organization
121 N184adf63d40d42e7a09ce593dd3ee4ae rdf:first sg:person.01102001105.13
122 rdf:rest N9dc024984e4e46e0b6fd559597fff625
123 N210fbd4aaba84bd3942f8d76c365f72b rdf:first sg:person.01167170416.01
124 rdf:rest N48755c80c41e453d8103c147034c317e
125 N3769c34120924ae9a9f26f04f0b54239 schema:name dimensions_id
126 schema:value pub.1128395219
127 rdf:type schema:PropertyValue
128 N3ba91b98bfee4cb780701388eb09d9f4 schema:volumeNumber 11
129 rdf:type schema:PublicationVolume
130 N48755c80c41e453d8103c147034c317e rdf:first sg:person.013775775106.11
131 rdf:rest N69a7336436d14b8795523a44feef281a
132 N489dcf1b889c4ba0985f468b07fef959 rdf:first sg:person.0632033303.17
133 rdf:rest Ne1289802612449fd8828a49daac3e88f
134 N555795172a004829a9fcc0a92b4d16fc schema:name pubmed_id
135 schema:value 32524494
136 rdf:type schema:PropertyValue
137 N69a7336436d14b8795523a44feef281a rdf:first sg:person.0733105733.74
138 rdf:rest N184adf63d40d42e7a09ce593dd3ee4ae
139 N9dc024984e4e46e0b6fd559597fff625 rdf:first sg:person.0654034520.21
140 rdf:rest rdf:nil
141 Ndfed84f958454cf1a39f274580b2d877 schema:issueNumber 7
142 rdf:type schema:PublicationIssue
143 Ne1289802612449fd8828a49daac3e88f rdf:first sg:person.01033602257.87
144 rdf:rest N210fbd4aaba84bd3942f8d76c365f72b
145 Ne7acc6ad7eac48179b422f0b108c20dc schema:name doi
146 schema:value 10.1007/s13300-020-00839-5
147 rdf:type schema:PropertyValue
148 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
149 schema:name Medical and Health Sciences
150 rdf:type schema:DefinedTerm
151 anzsrc-for:1103 schema:inDefinedTermSet anzsrc-for:
152 schema:name Clinical Sciences
153 rdf:type schema:DefinedTerm
154 anzsrc-for:1117 schema:inDefinedTermSet anzsrc-for:
155 schema:name Public Health and Health Services
156 rdf:type schema:DefinedTerm
157 sg:journal.1044057 schema:issn 1869-6953
158 1869-6961
159 schema:name Diabetes Therapy
160 schema:publisher Springer Nature
161 rdf:type schema:Periodical
162 sg:person.01033602257.87 schema:affiliation grid-institutes:grid.417540.3
163 schema:familyName Boye
164 schema:givenName Kristina S.
165 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01033602257.87
166 rdf:type schema:Person
167 sg:person.01102001105.13 schema:affiliation grid-institutes:grid.417540.3
168 schema:familyName Malik
169 schema:givenName Raleigh E.
170 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01102001105.13
171 rdf:type schema:Person
172 sg:person.01167170416.01 schema:affiliation grid-institutes:grid.417540.3
173 schema:familyName Mody
174 schema:givenName Reema
175 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01167170416.01
176 rdf:type schema:Person
177 sg:person.013775775106.11 schema:affiliation grid-institutes:None
178 schema:familyName Strizek
179 schema:givenName Alena Antonie
180 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.013775775106.11
181 rdf:type schema:Person
182 sg:person.0632033303.17 schema:affiliation grid-institutes:grid.459720.d
183 schema:familyName Robinson
184 schema:givenName Susan
185 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0632033303.17
186 rdf:type schema:Person
187 sg:person.0654034520.21 schema:affiliation grid-institutes:grid.459720.d
188 schema:familyName Kennedy-Martin
189 schema:givenName Tessa
190 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0654034520.21
191 rdf:type schema:Person
192 sg:person.0733105733.74 schema:affiliation grid-institutes:grid.417540.3
193 schema:familyName Konig
194 schema:givenName Manige
195 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0733105733.74
196 rdf:type schema:Person
197 sg:pub.10.1007/s00125-018-4729-5 schema:sameAs https://app.dimensions.ai/details/publication/pub.1107409514
198 https://doi.org/10.1007/s00125-018-4729-5
199 rdf:type schema:CreativeWork
200 sg:pub.10.1007/s12325-018-0805-y schema:sameAs https://app.dimensions.ai/details/publication/pub.1107826098
201 https://doi.org/10.1007/s12325-018-0805-y
202 rdf:type schema:CreativeWork
203 sg:pub.10.1007/s13300-018-0396-2 schema:sameAs https://app.dimensions.ai/details/publication/pub.1101407058
204 https://doi.org/10.1007/s13300-018-0396-2
205 rdf:type schema:CreativeWork
206 sg:pub.10.1007/s13300-019-0615-5 schema:sameAs https://app.dimensions.ai/details/publication/pub.1113754031
207 https://doi.org/10.1007/s13300-019-0615-5
208 rdf:type schema:CreativeWork
209 sg:pub.10.1007/s13300-019-0658-7 schema:sameAs https://app.dimensions.ai/details/publication/pub.1117490480
210 https://doi.org/10.1007/s13300-019-0658-7
211 rdf:type schema:CreativeWork
212 sg:pub.10.1007/s13300-021-01076-0 schema:sameAs https://app.dimensions.ai/details/publication/pub.1138660220
213 https://doi.org/10.1007/s13300-021-01076-0
214 rdf:type schema:CreativeWork
215 sg:pub.10.1186/s40842-018-0061-8 schema:sameAs https://app.dimensions.ai/details/publication/pub.1103875516
216 https://doi.org/10.1186/s40842-018-0061-8
217 rdf:type schema:CreativeWork
218 grid-institutes:None schema:alternateName Formerly of Global Patient Outcomes and Real-World Evidence, Eli Lilly, Sydney, Australia
219 schema:name Formerly of Global Patient Outcomes and Real-World Evidence, Eli Lilly, Sydney, Australia
220 rdf:type schema:Organization
221 grid-institutes:grid.417540.3 schema:alternateName Global Patient Outcomes and Real-World Evidence, Eli Lilly, Indianapolis, IN, USA
222 Medical Affairs, Eli Lilly, Indianapolis, IN, USA
223 schema:name Global Patient Outcomes and Real-World Evidence, Eli Lilly, Indianapolis, IN, USA
224 Medical Affairs, Eli Lilly, Indianapolis, IN, USA
225 rdf:type schema:Organization
226 grid-institutes:grid.459720.d schema:alternateName Kennedy Martin Health Outcomes (KMHO) Limited, Suite 404, The Dock Hub, Wilbury Villas, BN3 6AH, Hove, UK
227 schema:name Kennedy Martin Health Outcomes (KMHO) Limited, Suite 404, The Dock Hub, Wilbury Villas, BN3 6AH, Hove, UK
228 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...